InsiderTrades.com logo

XLO Insider Trading

Insider Ownership Percentage: 7.45%
Insider Buying (Last 12 Months): $72,966.18
Insider Selling (Last 12 Months): $0.00

Xilio Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Xilio Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Xilio Therapeutics Share Price & Price History

Current Price: $8.31
Price Change: ▲ Price Increase of +0.32 (4.01%)
As of 06/12/2026 04:00 PM ET

This chart shows the closing price history over time for XLO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Xilio Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2025James Samuel ShannonDirectorBuy1,785$9.66$17,243.105,000View SEC Filing Icon  
6/16/2025James Samuel ShannonDirectorBuy3,214$9.66$31,047.243,214View SEC Filing Icon  
6/16/2025Rene RussoCEOBuy2,592$9.52$24,675.8420,083View SEC Filing Icon  
1/2/2025Christopher James FrankenfieldCFOSell496$13.72$6,805.12887View SEC Filing Icon  
1/2/2025Kevin M BrennanSVPSell128$13.72$1,756.16228View SEC Filing Icon  
4/2/2024Gilead Sciences, Inc.Major ShareholderBuy34,660$10.64$368,782.40524,676View SEC Filing Icon  
2/8/2024Venture Fund Xi L.P. AtlasMajor ShareholderSell52$8.96$465.92144,254View SEC Filing Icon  
1/11/2024Venture Fund Xi L.P. AtlasMajor ShareholderSell111$12.18$1,351.98144,416View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Xilio Therapeutics (NASDAQ:XLO)

54.29% of Xilio Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XLO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Xilio Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2026Bain Capital Life Sciences Investors LLC7,372,686$4.72M0.4%+61.4%10.916%Search for SEC Filing on Google Icon
2/17/2026Ghisallo Capital Management LLC1,113,222$0.71M0.0%N/A1.648%Search for SEC Filing on Google Icon
2/16/2026Frazier Life Sciences Management L.P.5,915,091$3.79M0.1%N/A8.758%Search for SEC Filing on Google Icon
2/13/2026Velan Capital Investment Management LP170,000$0.11M0.1%N/A0.252%Search for SEC Filing on Google Icon
2/13/2026State Street Corp186,390$0.12M0.0%+13.7%0.276%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC42,080$27K0.0%N/A0.062%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC344,416$0.22M0.0%+68.3%0.510%Search for SEC Filing on Google Icon
2/11/2026Empery Asset Management LP1,183,040$0.76M0.7%N/A1.752%Search for SEC Filing on Google Icon
11/14/2025Squarepoint Ops LLC328,794$0.28M0.0%+39.6%0.634%Search for SEC Filing on Google Icon
8/15/2025Bridgeway Capital Management LLC56,081$38K0.0%-21.1%0.108%Search for SEC Filing on Google Icon
5/16/2025ADAR1 Capital Management LLC40,000$29K0.0%N/A0.077%Search for SEC Filing on Google Icon
4/29/2025Avantax Planning Partners Inc.150,399$0.11M0.0%N/A0.290%Search for SEC Filing on Google Icon
2/17/2025Trustees of Columbia University in the City of New York249,635$0.24M0.0%N/A0.568%Search for SEC Filing on Google Icon
2/17/2025Balyasny Asset Management L.P.343,230$0.33M0.0%+26.0%0.781%Search for SEC Filing on Google Icon
2/17/2025Aptus Capital Advisors LLC41,000$39K0.0%N/A0.093%Search for SEC Filing on Google Icon
2/14/2025Gilead Sciences Inc.9,105,451$8.70M0.6%N/A20.713%Search for SEC Filing on Google Icon
2/13/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC296,617$0.28M0.0%+11.4%0.675%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC358,422$0.34M0.0%+6.0%0.815%Search for SEC Filing on Google Icon
2/12/2025Takeda Pharmaceutical Co. Ltd.1,475,121$1.42M5.3%N/A3.356%Search for SEC Filing on Google Icon
2/6/2025Raymond James Financial Inc.50,086$48K0.0%N/A0.114%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC338,192$0.27M0.0%+85.0%0.769%Search for SEC Filing on Google Icon
8/12/2024XTX Topco Ltd33,289$32K0.0%N/A0.076%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC295,000$0.28M0.0%+18.3%0.799%Search for SEC Filing on Google Icon
5/6/2024Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690%Search for SEC Filing on Google Icon
4/22/2024PFG Investments LLC30,000$32K0.0%N/A0.087%Search for SEC Filing on Google Icon
2/15/2024Octagon Capital Advisors LP1,785,000$0.98M0.2%-23.0%6.481%Search for SEC Filing on Google Icon
11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047%Search for SEC Filing on Google Icon
8/15/2022Laurion Capital Management LP142,900$0.42M0.0%N/A0.520%Search for SEC Filing on Google Icon
7/27/2022Bailard Inc.36,632$0.11M0.0%N/A0.133%Search for SEC Filing on Google Icon
5/16/2022Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567%Search for SEC Filing on Google Icon
5/12/2022Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Xilio Therapeutics logo
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More on Xilio Therapeutics

Today's Range

Now: $8.31
Low: $7.90
High: $8.32

50 Day Range

MA: $8.23
Low: $7.68
High: $8.81

52 Week Range

Now: $8.31
Low: $6.47
High: $12.74

Volume

12,327 shs

Average Volume

25,310 shs

Market Capitalization

$54.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Xilio Therapeutics?

Xilio Therapeutics' top insider shareholders include:
  1. Gilead Sciences, Inc (Major Shareholder)
  2. Venture Fund Xi LP Atlas (Major Shareholder)
  3. Rene Russo (CEO)
  4. James Samuel Shannon (Director)
  5. Christopher James Frankenfield (CFO)
  6. Kevin M Brennan (SVP)
  7. Bain Capital Life Sciences Inv (Major Shareholder)
  8. Rock Springs Capital Managemen (Major Shareholder)
Learn More about top insider investors at Xilio Therapeutics.